Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4186)	4/13/2016 1:49:00 PM
From: GregorioAllegri	Read Replies (1) \| Respond to of 4474

Thanks. That is exactly what I am looking for. I am a bit surprised, though. Given that cancer, in general, causes a partial shut down in DNA repair, I would have guessed that the frequency of types and quantities of resistance should be similar between lung and breast cancers. There are probably numerous differences between breast and lung cells that cause them to differ. Considering the IC50s vs. EGFR and HER2 are both in the 2-25nM range, you would think the control would be similar in humans for controlling cancers caused by mutants of either, which should give us a shot at breast cancer. Does the patent list IC50s of any targets that could be safety concerns? GA